tiprankstipranks
Intellia Therapeutics (CH:38I)
:38I
Switzerland Market
38I
Intellia Therapeutics
RESEARCH TOOLSreports

Intellia Therapeutics (38I) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

38I Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
6 Buy
4 Hold
2 Sell
Based on 12 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

38I Stock 12 Month Forecast

Average Price Target

CHF16.97
▲(87.49% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is CHF16.97 with a high forecast of CHF39.78 and a low forecast of CHF7.31. The average price target represents a 87.49% change from the last price of CHF9.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"CHF6","23":"CHF23","40":"CHF40","14.5":"CHF14.5","31.5":"CHF31.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.78067058,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF39.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.967673777999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF16.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.3066537799999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF7.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,14.5,23,31.5,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.954,11.325282352307692,13.696564704615385,16.06784705692308,18.43912940923077,20.81041176153846,23.181694113846156,25.552976466153847,27.92425881846154,30.29554117076923,32.66682352307692,35.038105875384616,37.409388227692304,{"y":39.78067058,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.954,9.570436444461539,10.186872888923077,10.803309333384615,11.419745777846153,12.03618222230769,12.65261866676923,13.269055111230768,13.885491555692306,14.501928000153844,15.118364444615382,15.734800889076922,16.35123733353846,{"y":16.967673777999998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.954,8.82728106,8.70056212,8.57384318,8.44712424,8.320405300000001,8.193686360000001,8.06696742,7.94024848,7.813529539999999,7.686810599999999,7.560091659999999,7.4333727199999995,{"y":7.3066537799999995,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.954,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF39.78Average Price TargetCHF16.97Lowest Price TargetCHF7.31
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on CH:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF23.54
Buy
160.15%
Upside
Reiterated
08/14/26
Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target
Morgan Stanley Analyst forecast on CH:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF12.18
Hold
34.56%
Upside
Assigned
08/10/26
Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
H.C. Wainwright Analyst forecast on CH:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF20.3
Buy
124.27%
Upside
Reiterated
08/07/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on CH:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF15.43→CHF13.8
Hold
52.50%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on CH:38I
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.99→CHF19.48
Buy
115.30%
Upside
Upgraded
08/07/26
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
William Blair Analyst forecast on CH:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)
Canaccord Genuity Analyst forecast on CH:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF39.78
Buy
339.57%
Upside
Reiterated
08/06/26
Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target
Goldman Sachs Analyst forecast on CH:38I
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF7.31
Sell
-19.26%
Downside
Reiterated
08/06/26
Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs
RBC Capital Analyst forecast on CH:38I
Luca Issi
RBC Capital
RBC Capital
CHF12.18
Hold
34.56%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
Wolfe Research Analyst forecast on CH:38I
Andy Chen
Wolfe Research
Wolfe Research
CHF7.31
Sell
-19.26%
Downside
Downgraded
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)
Wedbush Analyst forecast on CH:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF9.74→CHF13.8
Hold
52.50%
Upside
Reiterated
07/10/26
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
TD Cowen Analyst forecast on CH:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/14/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
J.P. Morgan Analyst forecast on CH:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF6.49
Sell
-28.23%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on CH:38I
William Pickering
Bernstein
Bernstein
CHF10.55→CHF13.8
Hold
52.50%
Upside
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wells Fargo Analyst forecast on CH:38I
Yanan Zhu
Wells Fargo
Wells Fargo
CHF12.18
Hold
34.56%
Upside
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on CH:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF23.54
Buy
160.15%
Upside
Reiterated
08/14/26
Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target
Morgan Stanley Analyst forecast on CH:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF12.18
Hold
34.56%
Upside
Assigned
08/10/26
Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
H.C. Wainwright Analyst forecast on CH:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF20.3
Buy
124.27%
Upside
Reiterated
08/07/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on CH:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF15.43→CHF13.8
Hold
52.50%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on CH:38I
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.99→CHF19.48
Buy
115.30%
Upside
Upgraded
08/07/26
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
William Blair Analyst forecast on CH:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)
Canaccord Genuity Analyst forecast on CH:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF39.78
Buy
339.57%
Upside
Reiterated
08/06/26
Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target
Goldman Sachs Analyst forecast on CH:38I
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF7.31
Sell
-19.26%
Downside
Reiterated
08/06/26
Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs
RBC Capital Analyst forecast on CH:38I
Luca Issi
RBC Capital
RBC Capital
CHF12.18
Hold
34.56%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
Wolfe Research Analyst forecast on CH:38I
Andy Chen
Wolfe Research
Wolfe Research
CHF7.31
Sell
-19.26%
Downside
Downgraded
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)
Wedbush Analyst forecast on CH:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF9.74→CHF13.8
Hold
52.50%
Upside
Reiterated
07/10/26
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
TD Cowen Analyst forecast on CH:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/14/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
J.P. Morgan Analyst forecast on CH:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF6.49
Sell
-28.23%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on CH:38I
William Pickering
Bernstein
Bernstein
CHF10.55→CHF13.8
Hold
52.50%
Upside
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wells Fargo Analyst forecast on CH:38I
Yanan Zhu
Wells Fargo
Wells Fargo
CHF12.18
Hold
34.56%
Upside
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months
Mani ForooharLeerink Partners
Success Rate
14/39 ratings generated profit
36%
Average Return
+4.67%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 35.90% of your transactions generating a profit, with an average return of +4.67% per trade.
1 Year
Gena WangBarclays
Success Rate
10/26 ratings generated profit
38%
Average Return
-13.22%
Copying Gena Wang's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -13.22% per trade.
2 Years
Gena WangBarclays
Success Rate
8/26 ratings generated profit
31%
Average Return
-30.63%
Copying Gena Wang's trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -30.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

38I Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
10
13
10
5
6
Buy
4
5
5
4
3
Hold
13
17
13
10
7
Sell
2
4
4
4
3
Strong Sell
0
0
0
0
0
total
29
39
32
23
19
In the current month, 38I has received 9 Buy Ratings, 7 Hold Ratings, and 3 Sell Ratings. 38I average Analyst price target in the past 3 months is 16.97.
Each month's total comprises the sum of three months' worth of ratings.

38I Financial Forecast

38I Earnings Forecast

Next quarter’s earnings estimate for 38I is -CHF0.65 with a range of -CHF0.72 to -CHF0.59. The previous quarter’s EPS was -CHF0.65. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s earnings estimate for 38I is -CHF0.65 with a range of -CHF0.72 to -CHF0.59. The previous quarter’s EPS was -CHF0.65. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Sales Forecast

Next quarter’s sales forecast for 38I is CHF8.33M with a range of CHF0.00 to CHF12.21M. The previous quarter’s sales results were CHF6.24M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s sales forecast for 38I is CHF8.33M with a range of CHF0.00 to CHF12.21M. The previous quarter’s sales results were CHF6.24M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Stock Forecast FAQ

What is CH:38I’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 16.97.
    What is CH:38I’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 87.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Intellia Therapeutics a Buy, Sell or Hold?
          Intellia Therapeutics has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 2 sell ratings.
            What is Intellia Therapeutics’s share price target?
            The average share price target for Intellia Therapeutics is 16.97. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF39.78 ,and the lowest forecast is CHF7.31. The average share price target represents 87.49% Increase from the current price of CHF9.05.
              What do analysts say about Intellia Therapeutics?
              Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Intellia Therapeutics?
                To buy shares of CH:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.